CAR-T Cell Therapy

CAR-T Cell Therapy

Newer Agents on the Horizon for Refractory or Relapsed DLBCL

Although treating patients with R/R DLBCL remains challenging, some newer therapies on the horizon offer promise including CAR T-cell therapy.

The ASCO Post
B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma

Researchers generated B7-H3 targeted CAR-T-cells and tested their antitumor activities using patient derived tumor spheres.

Frontiers in Oncology
FDA Grants Orphan Drug Designation to Dual-Target CAR-T for Advanced Multiple Myeloma

The FDA granted orphan drug designation to GC012F, a novel chimeric antigen receptor T-cell therapy for the treatment of relapsed or refractory multiple myeloma.


Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma

Researchers examine the efficacy and safety of T cells containing a YYB-103 CAR that can preferentially bind to IL13Rα2 on MG cells.

Frontiers in Immunology
TCR T-Cell Therapy Induces Response in Solid Cancers

Half of patients achieved objective response to an infusion of IMA203, an autologous TCR-T cell therapy that is gene-edited to express a T-cell receptor recognizing PRAME protein in tumor cells.

Modified EASIX Score Predicts CRS and ICANS Before Severe Symptoms in Patients With B-Cell Malignancies

A modified version of the EASIX score, when calculated prior to and soon after CAR T-cell infusion, predicted severe CRS and ICANS before their occurrence. 

ASH Clinical News
Contextual Reprogramming of CAR-T Cells for Treatment of HER2+ Cancers

RB-340-1 is presented as an all-in-one T cell product that couples anti-HER2 CAR signaling to CRISPRi-mediated PD-1 gene suppression to prolong CAR-T cell persistence, enhancing treatment outcomes.

Journal of Translational Medicine
Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy

Researchers explore patient descriptions of key domains of health-related quality of life in DLBCL patients treated with CAR T therapy.

Oncology and Therapy
Incidence and Risk Factors Associated With Bleeding and Thrombosis Following Chimeric Antigen Receptor T-Cell Therapy

Bleeding episodes and thrombotic complications and their associated clinical and laboratory characteristics were recorded in a cohort of 127 consecutive patients... 

Blood Advances
Targeting Wnt Signaling in the Tumor Immune Microenvironment to Enhancing EpCAM CAR T-Cell therapy

Researchers find that the combination of EpCAM CAR T-cell therapy with the Wnt inhibitor can overcome the limitations of CAR T cells in treating solid tumors.

Frontiers in Pharmacology
Tunable Control of CAR T Cell Activity Through Tetracycline Mediated Disruption of Protein–Protein Interaction

This work shows how optimization of split-CAR structure affects function and adds a novel design allowing easy CAR inhibition through an FDA-approved small molecule.

Scientific Reports
CAR-T ‘Clearly Superior’ for Triple-Class Refractory Multiple Myeloma

Chimeric antigen receptor T-cell therapy has induced exceptional response rates among patients with relapsed or refractory multiple myeloma compared with conventional options. 

Generation of an NFκB-Driven Alpharetroviral “All-in-One” Vector Construct as a Potent Tool for CAR NK Cell Therapy

Researchers find that in contrast to T cells, the inclusion of NFκB-responsive elements within the inducible promoter construct was essential for CAR-inducible expression of the transgene.

Frontiers in Immunology
Demethylating Therapy Increases Anti-CD123 CAR T Cell Cytotoxicity Against Acute Myeloid Leukemia

Scientific findings indicate that AZA increases the immunogenicity of AML cells, enhancing recognition and elimination of malignant cells by highly efficient CTLA-4 - anti-CD123 CAR T cells.

Nature Communications
Researchers Develop a New Class of CAR-T Cells That Target Previously Untargetable Cancer Drivers

Researchers were able to identify peptides that are presented on the surface of tumor cells and can be targeted with PC-CARs, a new class of engineered T cells, stimulating an immune response...

Science Daily
CD38 CAR-T Cell Therapy May Be Promising for Patients With Multiple Myeloma

A novel CAR T-cell therapy targeting CD38 may be an effective option for multiple myeloma, according to research published in Frontiers in Oncology.

Hematology Advisor
FDA Delays Decision on Ciltacabtagene Autoleucel CAR-T for Advanced Multiple Myeloma

The FDA has delayed its decision on a biologics license application for ciltacabtagene autoleucel, a CAR T-cell therapy for treatment of adults with relapsed or refractory multiple myeloma.

Risk of Cytokine Release Syndrome After CAR T-Cell Therapy May Vary by Ethnicity

The risk of cytokine release syndrome after CAR T-cell therapy may vary by ethnicity and BMI, according to research presented at the 2021 AACR Conference on...

Cancer Therapy Advisor
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma

Anti-CD19 CAR-T cells have demonstrated activity against relapsed/refractory lymphomas.

Frontiers in Immunology
CAR T-Cell Therapies Show Similar Efficacy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A comparative analysis of the CAR T-cell therapies tisagenlecleucel and lisocabtagene maraleucel in patients with R/R DLBCL showed no significant differences in survival outcomes.

Cancer Therapy Advisor
T Cell Receptor-Mimic CAR-T Cell Specific for a Kinetochore Protein Targets Multiple Hematological Malignancies

Researchers have successfully used a mass spectrometry-based approach to design a TCR-mimic CAR T-cell specific to the kinetochore protein NDC80 that targets multiple cancer cell lines.

Hematology Advisor
Updated Safety and Efficacy of CAR-T Cell Therapy Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

A single dose of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, yielded early, deep, and durable responses in heavily pre-treated patients with R/R MM.

Hematology Advisor
Neuropsychiatric Disorders Common in Patients Who Receive CAR-T Therapy for Multiple Myeloma

More than one-quarter of patients who had CAR T-cell therapy for MM in 2018 had a neuropsychiatric disorder, according to results presented at the Annual SOHO Meeting.

Hematology Advisor
Brentuximab Vedotin Plus CHP Provides Lasting Benefit in Peripheral T-Cell Lymphoma

The survival benefits seen with brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone persist at 5 years, according to updated results from the ECHELON-2 trial.

Cancer Therapy Advisor
Hematologic Malignancies Linked to Higher Risk of COVID-19 and Severe Outcomes

A new study supports prior findings that patients with hematologic malignancies have an increased risk of developing COVID-19 and having severe outcomes, which include ICU admission and COVID-relat

Cancer Therapy Advisor

source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)